CIK 0001677077 · <br>Emerging growth company
Alzamend Neuro, Inc.
Sign in to watch- Ticker
- ALZN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Apr 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811822909
- Phone
- 844-722-6333
- Business address
- 480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA, GA, 30326
- 4 Open-market buy Director bought 100 shares at $0.68 ($68)
- DEF 14A Proxy Proxy Statement
- S-3 Offering Registration Statement
- 10-Q Report Quarterly Report
- 8-K Event Bylaws or fiscal year change
- PRE 14A Proxy Proxy Statement (Preliminary)
- 8-K Event Material agreement · Unregistered share sale
- 8-K Event Results of operations
- 10-Q Report Quarterly Report
- 8-K Event Regulation FD disclosure
- 424B5 Offering Prospectus
- 8-K Event Material agreement
- 10-Q Report Quarterly Report
- 4 Open-market buy Director bought 75 shares at $2.75 ($206)
- 4 Open-market buy Director bought 25 shares at $3.74 ($93)
- 8-K Event Regulation FD disclosure
- 10-K Report Annual Report
- NT 10-K Other NT 10-K
- 8-K Event Bylaws or fiscal year change · Regulation FD disclosure
- 424B3 Offering Prospectus
Page 5 of 20 · 398 filings